At the moment, the assessment of MSI in cancer cells, the detection of EBV-infected cancer cells, and the expression of PDL-1 in cancer cells or in the immune-infiltrating cells are the emerging markers that are likely to change the adjuvant/perioperative approach of gastric cancer, as detailed below. Here, CD274 is linked to gastric cancer.